Chen Hong-Bin, Huang Yue, Dai Dong-Ling, Zhang Xia, Huang Zhong-Wen, Zhang Qi-Kai, Wang Hui-Hua, Zhang Jun-Su, Pan Ge
Department of Gastroenterology, Sanming Municipal First Hospital, Sanming 365000, China.
Hepatobiliary Pancreat Dis Int. 2004 Feb;3(1):55-7.
The resection rate of primary liver tumor in China is only about 20%. A lot of patients with moderate and advanced liver tumor may lose the chance of operation. The objective of present research was to study the efficacy of transcatheter arterial chemoembolization (TACE) combined with percutaneous injection of chemical agents and acetic acids in the treatment of patients with primary liver cancer (PLC).
Thirty-three patients with middle and advanced stage of PLC were divided into two groups: percutaneous injection of chemical agents and acetic acids (15 patients, group A) and TACE (18 patients, group B).
Tumor diameter and serum AFP level reduced to 86.6% and 83.3% in group A, and 55.5% and 40% in group B, respectively. There was significant difference between the two groups (P<0.01). The 1, 2, 3, 4-year survival rates of group A were 96.7%, 86.6%, 51.3%, 33.3%, respectively and in group B were 66.7%, 44.4%, 16.7%, 0%, respectively (P<0.01).
TACE combined with percutaneous injection of chemical agents and acetic acids is efficacious to increase the survival rate of patients with PLC.
我国原发性肝癌的切除率仅约20%。许多中晚期肝癌患者可能会失去手术机会。本研究的目的是探讨经导管动脉化疗栓塞术（TACE）联合经皮注射化学药物及醋酸治疗原发性肝癌（PLC）患者的疗效。
将33例中晚期PLC患者分为两组：经皮注射化学药物及醋酸组（15例，A组）和TACE组（18例，B组）。
A组肿瘤直径和血清甲胎蛋白水平分别降至86.6%和83.3%，B组分别降至55.5%和40%。两组间差异有统计学意义（P<0.01）。A组1、2、3、4年生存率分别为96.7%、86.6%、51.3%、33.3%，B组分别为66.7%、44.4%、16.7%、0%（P<0.01）。
TACE联合经皮注射化学药物及醋酸可有效提高PLC患者的生存率。
